干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现

免费注册账号
查看全文和研发动态、知识导航以及收藏您喜欢的数据等操作,您需要注册一个免费帐户并登录。

写笔记

您最近的笔记
Drug Name:Ovapuldencel-T
Regulatory Designations:     
Originator Company: Neostem Oncology Active Companies: Neostem Oncology
Last Change Date: 2018-03-21

extract

NeoStem Oncology (formerly California Stem Cell (CSC), until the acquisition of CSC by Caladrius Biosciences ), is investigating Ovapuldencel-T (presumably CLBS-23), a combination of autologous dendritic cells treated with GM-CSF and loaded with irradiated autologous tumor cell antigens, for the potential sc treatment of metastatic ovarian cancer, fallopian tube cancer and peritoneal cancer [ 1518203 ], [ 1518006 ], [ 1554915 ], [ 1554947 ], [ 1664765 ], [ 1697569 ]. In October 2017, a phase II trial


Other Drug Names:

CLBS-23; Ovapuldencel-T; autologous dendritic cells loaded with tumor antigens + GM-CSF (ovarian/fallopian tube/peritoneal cancer), NeoStem Oncology; irradiated tumor cell antigens loaded autologous dendritic cells + GM-CSF (ovarian/fallopian tube/peritoneal cancer), California Stem Cell

Technologies

Biological therapeutic; Subcutaneous formulation

Development Status (Current)

Neostem Oncology: US: Discovery: Fallopian tube cancer: 31-Jul-2013 Neostem Oncology: US: Discovery: Peritoneal tumor: 31-Jul-2013 Neostem Oncology: US: Discovery: Metastatic ovary cancer: 31-Jul-2013

Development Status (History)


Drug Development Phase

[Fallopian tube cancer: Discovery: US Peritoneal tumor: Discovery: US Metastatic ovary cancer: Discovery: US]

Therapy Area:

Cancer


Highest Status

Discovery


Target-based Actions


Other Actions

Anticancer; Dendritic cell vaccine; Immunomodulator; Therapeutic vaccine


Active Indications

Fallopian tube cancer; Metastatic ovary cancer; Peritoneal tumor